A Texas Children’s Hospital investigator won a $2.4 million NIH grant for ALS and other neurodegenerative disease research.
RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve ...
NeuroSense plans to apply to Canada’s regulators for early marketing approval of the oral therapy, supported by a Phase 2b ...
Avextra plans a Phase 2 trial in Italy to test a cannabis-based oral medicine to ease symptoms in ALS and other ...
Researchers have developed a type of gene therapy that selectively targets diseased nerve cells in ALS while leaving healthy ...